Evidence Hub

Right Ventricular Phenotyping Can Lead to Pulmonary Vascular Therapy Response in Those with Pulmonary Hypertension with COPD: A Single-Center Cohort Study

Salako O, Singh A

Journal of cardiovascular development and disease, 2025

Abstract

Pulmonary hypertension (PH) with chronic obstructive pulmonary disease (COPD) is associated with poor survival with no approved therapies. We report on the response to inhaled treprostinil (iTRE) of a small retrospective cohort of PH-COPD patients with a baseline "PH-right ventricular (RV) phenotype", defined by a RV-dependent circulatory limitation derived from a combination of echocardiographic and hemodynamic criteria. Patients were started on inhaled treprostinil with significant improvement in six-minute walk distance, NT-proBNP, and improved RV metrics by echocardiography. The preliminary findings of this cohort provide evidence for the importance of precision phenotyping of PH-COPD.

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free